Mar 03, 2016 13:00 pm UTC| Business
EXTON, Pa., March 03, 2016 -- Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing transformational therapies for diseases affecting the skin, connective tissue and...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results on March 10, 2016
Mar 03, 2016 13:00 pm UTC| Business
SHELTON, Conn., March 03, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively...
Stemline Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference
Mar 03, 2016 13:00 pm UTC| Business
NEW YORK, March 03, 2016 -- Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the Cowen and Company 36th Annual Health Care Conference on Wednesday,...
Mar 03, 2016 13:00 pm UTC| Business
SCOTTSDALE, Ariz., March 03, 2016 -- The Joint Corp. (NASDAQ:JYNT), a national healthcare operator, manager and franchisor of chiropractic clinics, today announced that it will release its 2015 fourth quarter and full...
Proofpoint to Present at Piper Jaffray Technology Symposium Series
Mar 03, 2016 13:00 pm UTC| Business
SUNNYVALE, Calif., March 03, 2016 -- Proofpoint, Inc. (NASDAQ:PFPT), a leading next-generation cybersecurity company, today announced that Manish Sarin, executive vice president, corporate planning development, will...
UBIC Names Andy F. Jimenez as Corporate Officer by the Board
Mar 03, 2016 13:00 pm UTC| Business
TOKYO, March 03, 2016 -- UBIC, Inc. (Nasdaq:UBIC) (TSE:2158), a leading provider of international litigation support and big-data analysis services, announced today that its Board of Directors has named Andy F. Jimenez,...
Immune Design to Report Fourth Quarter and Year End 2015 Financial Results
Mar 03, 2016 13:00 pm UTC| Business
SEATTLE and SOUTH SAN FRANCISCO, March 03, 2016 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth quarter and year end 2015 financial...